AZ COMPLETES ACQUISITION OF TAKEDA RESPIRATORY

ASTRAZENECA COMPLETES ACQUISITION
OF TAKEDA'S RESPIRATORY BUSINESS

AstraZeneca today announced that it has completed the acquisition of the core respiratory business of Takeda Pharmaceutical Company Limited ("Takeda"). The agreement, announced in December 2015, includes the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease. AstraZeneca has marketed Daliresp in the US since the acquisition of the rights from Actavis in the first quarter of 2015.

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com


CONTACTS

Media Enquiries   
Neil   Burrows UK/Global +44   20 7604 8032
Vanessa   Rhodes UK/Global +44   20 7604 8037
Karen   Birmingham UK/Global +44   20 7604 8120
Jacob   Lund Sweden +46   8 553 260 20
Abigail Bozarth US +1   302 885 2677
Investor   Enquiries
UK
Thomas Kudsk Larsen +44 7818 524185
Eugenia Litz RIA  +44 7884 735627
Nick Stone CVMD  +44 7717 618834
Craig Marks Finance +44 7881 615764
Christer Gruvris Consensus Forecasts +44   7827 836825
US
Lindsey Trickett  Oncology,   ING +1   240 543 7970
Mitch Chan  Oncology +1   240 477 3771
Dial / Toll-Free +1   866 381 7277

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease,
ING - Infection, Neuroscience and Gastrointestinal

03 May 2016

-ENDS-

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com

Subscribe

Documents & Links